Noninvasive Mechanical Ventilation and Neuropsychiatric Disorders: Essential Practical Approaches 3031279670, 9783031279676

Table of contents :
Contents
Abbreviations
Part I: Neuropsychiatric and Lung Physiology
1: Case Report: Delirium Permanence During Resolution Phase of Massive Pneumonia in Patient with COPD Exacerbation
1.1 Clinical Case
1.2 Discussion
1.2.1 Definition of Delirium
1.2.2 Risk Factors for Delirium
1.2.3 Acid–Base Balance and Noninvasive Mechanical Ventilation
1.2.4 APACHE II Score
1.2.5 Infectious or Sepsis: The EEG Role
1.3 Delirium as a Main Risk Factor in Community-Acquired Pneumonia (CAP)
1.4 Pharmacological Treatment of Lower Respiratory Tract Infections (LTRI)
1.5 Conclusions
References
2: Patterns of Psychology Responses in Acute and Chronic Respiratory Failure
2.1 Introduction
2.2 Psychological Response in Acute Respiratory Failure
2.3 Psychological Response in Chronic Respiratory Failure
2.4 Conclusive Remarks
References
3: Epidemiology of Neuropsychiatric Disorders in Ventilator Management
3.1 Anxiety
3.2 Agitation
3.3 Delirium
3.4 Depression
3.5 Sleep Disorders
3.6 Stress Disorders
References
Part II: Psychiatric Disorders in Respiratory Failure: Key Concepts
4: Psychiatric Disorders and Respiratory Failure: Key Concept
4.1 Introduction
4.2 Definition and Magnitude of Problem
4.2.1 How to Assess Anxiety Disorders, Depression, and PTSD?
4.2.2 Risk Factors for Anxiety Disorders, Depression, and PTSD
4.2.3 Pathophysiology
4.2.4 Long-Term Potentiation and Stress-Related Memory
4.2.5 Treatment
4.3 Delirium and Dementia
4.3.1 Screening Tools for Delirium
4.3.2 Risk Factors, Prevention and Treatment of Delirium
4.3.3 Dementia
References
5: Concept of “Vulnerable to Stress” Critical Illness-Psychological Stress and Susceptibility in Noninvasive Ventilator Support
5.1 Vulnerable to Stress
5.2 Resilience to Stress
5.3 Why Is the Stress Vulnerability Important in NIV?
5.4 Mechanism of Stress Adaptation
5.5 Factors Related with Stress Vulnerability/Resilience
5.5.1 Vulnerability
5.5.2 Resilience
5.5.3 Health-Related Resilience
5.6 Psychological Impact of Acute and Chronic Illnesses that May Require NIMV
5.7 How to Strengthen Psychological Resilience During NIMV
5.8 Conclusion
References
6: Evaluation of Susceptibility to Psychological Stress and Psychopathology in Non-invasive Ventilatory Support
6.1 Introduction
6.2 The Concept of Susceptibility
6.3 The Concept of Psychological Stress
6.4 The Problem of the ‘Threshold’ in Psychopathology
6.5 Psychological Stress and Psychopathology in Patients with Non-invasive Ventilatory Support
6.6 Assessing Susceptibility in Patients with Non-invasive Ventilatory Support
6.7 Conclusions
References
Part III: Acute Psychiatric Disorders That May Develop During Noninvasive Ventilator Support: Acute and Chronic Condition
7: Measurements and Scores: Hospital Anxiety and Depression Scale (HADS)
7.1 Questionnaire and Scoring
7.2 Interpretation of Results
7.3 Validation of HADS
7.4 Copyright Information
7.5 Criticism
7.6 Conclusions
References
8: Anxiety: Hiperventilation Syndrome
References
9: Depression and Noninvasive Ventilation
9.1 Introduction
9.1.1 Epidemiology
9.1.2 Etiology
9.1.3 Comorbidity and Differential Diagnosis
9.2 Depression and NIV
9.3 Management of Depression in NIV
9.4 Conclusions
References
10: Post-traumatic Stress Disorder
10.1 Introduction
10.1.1 Epidemiology
10.1.2 Etiology
10.1.3 Comorbidity and Differential Diagnosis
10.2 PTSD and NIV
10.3 Management of PTSD in NIV and ICU
10.4 Conclusions
References
11: Delirium
11.1 Definition
11.2 Prevalence in Community, Hospital and ICU Setting
11.3 Pathophysiology
11.4 Predisposing and Precipitating Factors
11.5 Clinical Manifestations and Subtypes
11.6 Diagnosis
11.7 Outcome
11.8 Management of Delirium
11.9 Therapy
11.9.1 Non-pharmacological Therapy
11.9.2 Pharmacological Therapy
11.10 Therapy in ICU
11.10.1 Pharmacological Therapy
11.11 The Controversial Relationship Between NIV e Delirium
11.11.1 Delirium as Enemy of NIV
11.11.2 NIV as an Ally for Patients with Delirium
11.11.3 NIV as Promoter of Delirium
11.12 Conclusive Remarks
References
Part IV: Diagnosis of Psychiatric Disorders in Respiratory Failure: Non-invasive Ventilator Support
12: Risk Factors for Prolonged Psychiatric Morbidity During Noninvasive Ventilator Support
12.1 Introduction
12.2 Characteristics of the Device and Psychiatric Morbidity
12.2.1 The Types of Noninvasive Mechanical Ventilators
12.2.2 Noninvasive Mechanical Ventilator Settings
12.3 Implementation Process and Psychiatric Morbidity
12.3.1 Features of the Place of Application
12.3.2 Duration of Application
12.4 Patient Characteristics and Psychiatric Morbidity
12.4.1 Stress Response and Coping Styles of Patients
12.4.2 Patients’ Feelings of Fear and Discomfort
12.4.3 Lifestyle Changes and Patient Perceptions of Treatment
12.5 Characteristics of the Health Care Practitioner and Psychiatric Morbidity
12.6 Conclusion
References
Part V: Noninvasive Ventilation: Acute Respiratory Failure
13: Psychopathological Problems in Chronic Obstructive Pulmonary Disease (C.O.P.D.): An Holistic “Mind-Body” Comprehension
13.1 Introduction
13.2 Psycho-dynamic Premises
13.2.1 Etiology and Pathophysiology of Psychopathological Disorders in C.O.P.D. Patients
13.3 The Extent of Prevalence of Mental Disorders in C.O.P.D. Patients: Epidemiological Background
13.4 Panic Attacks
13.4.1 How to Quantify Mental Disorders in C.O.P.D. Patients?
13.4.1.1 Potential Screening Tools
13.4.1.2 Pharmacological and Psychological Intervention
13.5 Depression in C.O.P.D. Patients: Biological and Psychological Interpretation
13.5.1 Depression Therapy: Antidepressant Medication
13.5.2 Managing Anxiety in C.O.P.D. Patients
13.5.3 Psychological Therapies for the Treatment of Depression in Patients with C.O.P.D.
13.6 Conclusions
13.7 Final Remarks
References
14: Noninvasive Ventilation in Asthma
14.1 Introduction
14.2 Respiratory System Mechanics and Gas Exchange in Acute Exacerbations
14.3 Use of NIV in Asthma
14.4 Difficulties of NIV During Asthma Exacerbations
14.5 Physiological Basis of NIV in Acute Asthma
14.6 Practical Approaches in NIV Application
14.7 Conclusions
References
15: Neuromuscular Disorders
15.1 Introduction
15.2 Neuromuscular Diseases
15.3 Symptoms and Signs of Neuromuscular Diseases
15.4 Monitoring Patients with Neuromuscular Diseases
15.5 Noninvasive Ventilation in Patients with Neuromuscular Diseases
References
16: Acute Respiratory Failure in Pneumonia
16.1 According to the Anatomical Placement
16.2 According to the Etiology
16.2.1 Infectious
16.2.2 Noninfectious
16.3 According to the Clinical Picture
16.4 According to the Empirical Treatment Approach
16.4.1 Pneumonia Developed in Immunocompromised Patients
16.5 Others
16.6 Effect of Positive Airway Pressure on Circulatory System
16.7 Effects of Continuous Positive Airway Pressure on the Respiratory System
16.8 Respiratory Support to the Special Conditions with Pneumonia
References
17: Acute Neurological Disorders
17.1 Acute Neurological Disorders
17.2 Recognition of Acute Neuromuscular Respiratory Failure
17.3 Basic Principles of Noninvasive Mechanical Ventilation
17.4 Indications of Noninvasive Mechanical Ventilation in Acute Neurological Disorders
References
18: Noninvasive Ventilation in a Pandemic, Bioterrorism, High-Risk Infections
18.1 Introduction
18.2 Bioterrorism
18.3 High-Risk Infections and Pandemic
18.4 Conclusion
References
Untitled
19: Long-Term Ventilator-Dependent Patients: Noninvasive Ventilation
19.1 Definition
19.2 Pathophysiology
19.3 Indications of Long-Term Noninvasive Mechanic Ventilation
19.4 Initiating and Management of Ventilation Process
References
Part VI: Noninvasive Ventilation: Chronic Respiratory Failure
20: Sleep-Related Breathing Disorders
20.1 Background and Epidemiological Perspective
20.2 Pathophysiology and Management
20.3 Conclusions and Future Perspectives
References
21: Psychotic Disorders and NIV
21.1 Introduction
21.2 More Frequent Clinical Pictures
21.3 Psychosis and NIV
References
22: Neurodegenerative Disorders/Dementia
22.1 Introduction
22.2 Cognitive Symptoms in Dementia
22.3 Functional Limitations and Stages of Dementia
22.4 Behavioural Disorders in Dementia
22.5 Causes of Behavioural and Psychological Symptoms of Dementia (BPSD)
22.6 Dementia and Comorbidities
22.7 Noninvasive Ventilation in People with Dementia
22.7.1 The Level of Cognitive Impairment
22.7.2 The Stage of Dementia
22.7.3 The Presence of BPSD
22.7.4 Caregiver Stress and Burn out
References
23: Chronic Neurological Disorders
23.1 Neuromuscular Diseases (NMDs)
23.1.1 Pathophysiology of Respiratory Failure in Neuromuscular Disease
23.1.2 Respiratory Management in NMDs
23.1.3 Nocturnal and Daily Non-invasive Mechanical Ventilation in NMDs
23.2 Motor Neurone Disease (MND)
23.3 Duchenne Muscular Dystrophy (DMD)
23.4 Spinal Muscular Atrophy (SMA)
23.5 Post-polio Syndrome (PPS)
23.6 Disorders of Neurological Control of Breath
23.7 Congenital Neurologic Disease Associated with Central Hypoventilation
23.7.1 Chiari Malformation
23.7.2 Congenital Central Hypoventilation Syndrome
23.8 Acquired Neurologic Disorders of Control of Breath
23.8.1 Spinal Cord Injury
23.8.2 Cerebral Tumours
23.8.3 Infections
23.9 Conclusions
References
Part VII: Outcome, Quality of Life, Palliative Care
24: Risk Factors for Prolonged Psychiatric Morbidity During Noninvasive Ventilator Support
24.1 Introduction
24.2 Characteristics of the Device and Psychiatric Morbidity
24.2.1 The Types of Noninvasive Mechanical Ventilators
24.2.2 Noninvasive Mechanical Ventilator Settings
24.3 Implementation Process and Psychiatric Morbidity
24.3.1 Features of the Place of Application
24.3.2 Duration of Application
24.4 Patient Characteristics and Psychiatric Morbidity
24.4.1 Stress Response and Coping Styles of Patients
24.4.2 Patients’ Feelings of Fear and Discomfort
24.4.3 Lifestyle Changes and Patient Perceptions of Treatment
24.5 Characteristics of the Healthcare Practitioner and Psychiatric Morbidity
24.5.1 Meeting the Patient’s Information Needs
24.6 Conclusion
References
25: Neurology and Psychiatric Sequelae of Intensive Care: Impact on Quality of Life
25.1 In Patients Without Initial Acute Brain Damage
25.2 In Patients with Initial Acute Brain Damage
25.3 Neurological Symptomatology
25.4 Psychiatric Symptomatology
25.5 Impact on Quality of Life
References
26: Neurology and Psychiatric Disorders: Long-Term Implications for the Healthcare System
26.1 Introduction
26.2 Intensive Care Can Lead to Mental Disorders, Cognitive Impairment, and Disability
26.3 People with Neurology and Psychiatric Disorders May Have Greater Need of NIV
26.3.1 COPD and Mood Disorders
26.3.2 COPD and Dementia
26.3.3 OSAS
26.4 Why Mental and Psychiatric Disorders Matter for Global Health?
26.5 Cost of Neurological and Psychiatric Diseases for Society and for Healthcare System
26.5.1 Direct Costs
26.5.1.1 Cost of NIV in General People, in Acute and in Chronic Setting
26.5.1.2 The Cost of NIV in Patients with Neurology and Psychiatric Disorders
26.5.2 Indirect Costs
26.5.2.1 The Costs of Dementia: An Example of Pathology with High Economic and Social Impact
26.5.2.2 NIV in Patients with Dementia and Palliative Care: An Example of Costs and Benefits Beyond Economic Calculation
26.6 Long-Term Implications: Quality of Life and Mortality
26.6.1 Mortality in Mental Disorders and Global Disease Burden Implications
26.6.2 Neurology and Psychiatric Disorders and Implications for Healthcare System: Is It an Adjustment or Implementation of Care Necessary? Are We Doing What We Can? Can We Do Better?
26.6.3 Can We Reduce and Prevent the Burden of Neurology and Psychiatric Disease?
26.7 Conclusive Remarks
References
27: Neurocognitive and Emotional Morbidity and Quality of Life
27.1 Benefits of Noninvasive Ventilation Treatments on Acute Respiratory Distress Syndrome Patients: A Psychological Perspective
27.2 Impact of Noninvasive Ventilation Treatment on Chronic Respiratory Failure Patients’ Cognitive and Psychological Aspects
27.2.1 Cognitive and Psychological Symptoms in Chronic Respiratory Failure Patients
27.2.2 Cognitive and Psychological Outcomes of Noninvasive Ventilation Treatments
References
28: Psychological, Social, and Economic Impacts
28.1 Introduction
28.2 Impact of NIV on CRF
28.2.1 Partner Quality of Life and Relationship Satisfaction
28.2.2 Economic Burden
28.3 Psychological, Social, and Economic Impacts of NIV on Palliative Care: Family Members and Healthcare Professional Perceptions
28.4 Conclusion
References
29: Neurology and Psychiatric Cognitive Recovery
29.1 Neurofunctional, Neuroanatomical, and Cognitive Changes Related to Respiratory Failure. What Challenges for Recovery?
29.1.1 Obstructive Sleep Apnea Syndrome
29.1.2 Acute Respiratory Distress Syndrome and Brain Injury
29.1.3 Amyotrophic Lateral Sclerosis
References
30: Non Invasive Ventilation
30.1 Introduction
30.2 Ethical Evaluation
30.3 NIV and DNI
30.4 DNI and Psychiatric Disorders
30.5 DNI and Neurological Disorders
30.6 Conclusion
References
31: Neuropsychiatric Disorders in Pulmonary Rehabilitation
31.1 Introduction
31.2 Neuropsychological Impairment/Cognitive Dysfunction
31.3 Anxiety
31.4 Depression
31.5 Pathogenesis of Neuropsychiatric Disorders in Chronic Lung Disease
31.6 Role of Pulmonary Rehabilitation in Neuropsychiatric Disorders
References
Part VIII: Treatment: Interventions and Prevention
32: Physical Activity/Emotional Response in Non-invasive Ventilator Users
32.1 Background
32.2 The Decision-Making Process
32.3 Conclusion
References
33: New Technologies (Tele-Health and Other Trends) Directed in Neurology and Psychiatric Disorders in Home Care
33.1 Telemedicine and Tele-Health: Definition
33.2 Telemedicine and Tele-Health: Terminology
33.3 Technologies Used in Telemedicine and Tele-Health in Mental Disorders
33.3.1 Videoconferencing Services
33.3.2 Websites
33.3.3 Smartphones
33.3.4 Social Media
33.3.5 Chatbots
33.3.6 Virtual Reality
33.4 Benefits of Telemedicine and Tele-Health in Mental Disorders
33.5 Telemedicine and Tele-Health in Mental Disorders During COVID-19 Pandemic
33.6 Telemedicine and Tele-Health in Neurologic Diseases
33.6.1 Parkinson’s Disease and Essential Tremor
33.6.2 Dystonia
33.6.3 Huntington Disease
33.6.4 Tourette Syndrome
33.6.5 Neuromuscular Diseases
33.6.6 Stroke
33.6.7 Dementia
33.7 Telemedicine and Tele-Health in Psychiatric Diseases
33.7.1 Anxiety, Panic Disorder, and Depression
33.7.2 Schizophrenia and Psychosis
33.7.3 Eating Disorders
33.7.4 Telemedicine and Tele-Health in Emergency: Prevention of Suicide
33.7.5 Telemedicine and Tele-Health and Adherence to Therapy in Psychiatric Disorders
33.8 Conclusive Remarks
References
34: Prevention Tools for Neurology and Psychiatric Disorders in Noninvasive Ventilation (Delirium Prevention/Management Sleep Promotion)
34.1 Delirium in NIV: Background and Assessment
34.2 Predisposing and Precipitating Factors of Delirium
34.3 Nonpharmacological Prevention and Management
34.4 Pharmacological Intervention
References
Part IX: Further Research
35: The Role of Neurocognitive Disorders in Sustaining “Ageism as a Key Factor for Noninvasive Ventilation Failure”
35.1 Introduction
35.2 Ageism: Historical Background
35.2.1 Ageism: Definition, Operationalized Concept, and Black Holes
35.3 Ageism and Its Impact on the Healthcare
35.4 The Usefulness of NIMV in Caring for Critically Old Patient
35.5 Neurocognitive Disorders: Clusters, an Etiological Subtype, and Epidemiology
35.6 Neuropsychiatric Disorders and Aging: A Deleterious Cocktail for Ageist Culture
35.7 Stigma Reduction Interventions in the Healthcare System
35.8 Conclusions
References
36: Neuropsychiatric Disorders During Non-Invasive Ventilation
36.1 A Global View of the Problem
36.2 A Multidimensional View of the Problem
36.3 Conclusion
References

Citation preview

Noninvasive Mechanical Ventilation and Neuropsychiatric Disorders Essential Practical Approaches Antonio M. Esquinas Editor-in-Chief Andrea Fabbo Filiz Koc Agnieszka Prymus Małgorzata Farnik Editors

123

Noninvasive Mechanical Ventilation and Neuropsychiatric Disorders

Antonio M. Esquinas  •  Andrea Fabbo Filiz Koc  •  Agnieszka Prymus  Małgorzata Farnik Editors

Noninvasive Mechanical Ventilation and Neuropsychiatric Disorders Essential Practical Approaches

Editors Antonio M. Esquinas Intensive Care Unit Hospital General Universitario Morales Meseguer Murcia, Murcia, Spain Filiz Koc Department of Psychiatry and Neurology Cukurova University Adana, Türkiye

Andrea Fabbo Cognitive Disorders and Dementia Unit University of Modena and Reggio Emilia Modena, Italy Agnieszka Prymus Psychoneuroimmunology and Psychopharmacology Medical University of Silesia Katowice, Poland

Małgorzata Farnik Department of Pneumonology Medical University of Silesia Katowice, Poland

ISBN 978-3-031-27967-6    ISBN 978-3-031-27968-3 (eBook) https://doi.org/10.1007/978-3-031-27968-3 © The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2023 This work is subject to copyright. All rights are solely and exclusively licensed by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, expressed or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. This Springer imprint is published by the registered company Springer Nature Switzerland AG The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland

Contents

Part I Neuropsychiatric and Lung Physiology 1

Case Report: Delirium Permanence During Resolution Phase of Massive Pneumonia in Patient with COPD Exacerbation��������������������������������������������������������������������������   3 Corrado Mollica, Enrico Maialetti, Francesco Alessandri, and Daniela Sollazzo

2

Patterns of Psychology Responses in Acute and Chronic Respiratory Failure��������������������������������������������������������������������  19 Marilena De Guglielmo and Giuseppina Fabbo

3

Epidemiology of Neuropsychiatric Disorders in Ventilator Management ������������������������������������������������������  31 Bahadır Demir

Part II Psychiatric Disorders in Respiratory Failure: Key Concepts 4

 Psychiatric Disorders and Respiratory Failure: Key Concept��������������  45 Dipasri Bhattacharya, Antonio M. Esquinas, and Mohanchandra Mandal

5

Concept of “Vulnerable to Stress” Critical Illness-Psychological Stress and Susceptibility in Noninvasive Ventilator Support�����������������������������������  59 Şengül Kocamer Şahin

6

Evaluation of Susceptibility to Psychological Stress and Psychopathology in Non-invasive Ventilatory Support ����������������������������������������������������������������������������������  73 Alessandro Colucci-D’Amato, Anna Annunziata, and Giuseppe Fiorentino

v

Contents

vi

Part III Acute Psychiatric Disorders That May Develop During Noninvasive Ventilator Support: Acute and Chronic Condition 7

Measurements and Scores: Hospital Anxiety and Depression Scale (HADS)��������������������������������������������������������������������������  83 Małgorzata Farnik

8

Anxiety: Hiperventilation Syndrome ������������������������������������������������������  89 Tânia Filipa Carneiro Teixeira

9

Depression and Noninvasive Ventilation��������������������������������������������������  93 João Quarenta, Sofia Neves Martins, Tânia Teixeira, and Sérgio do Nascimento Ferreira

10 Post-traumatic Stress Disorder���������������������������������������������������������������� 101 Sofia Neves Martins, Tânia Teixeira, João Quarenta, and Bruno Ribeiro 11 Delirium������������������������������������������������������������������������������������������������������ 107 Angela Mancini and Andrea Fabbo Part IV Diagnosis of Psychiatric Disorders in Respiratory Failure: Non-invasive Ventilator Support 12 Risk  Factors for Prolonged Psychiatric Morbidity During Noninvasive Ventilator Support�������������������������������������������������� 129 Soner Çakmak Part V Noninvasive Ventilation: Acute Respiratory Failure 13 Psychopathological  Problems in Chronic Obstructive Pulmonary Disease (C.O.P.D.): An Holistic “Mind-Body” Comprehension������������������������������������������������������������������������������������������ 145 Giacomo Gatti, Mario Giordano, and Corrado Mollica 14 Noninvasive Ventilation in Asthma ���������������������������������������������������������� 161 Pelin Pınar Deniz 15 Neuromuscular Disorders ������������������������������������������������������������������������ 167 Dušanka Obradović 16 Acute  Respiratory Failure in Pneumonia������������������������������������������������ 173 Ozlem Ozkan Kuscu and Ferit Kuscu 17 Acute Neurological Disorders ������������������������������������������������������������������ 179 Turgay Demir and Filiz Koc 18 Noninvasive  Ventilation in a Pandemic, Bioterrorism, High-Risk Infections���������������������������������������������������������� 187 Nicola Vargas, Loredana Tibullo, and Andrea Fabbo

Contents

vii

19 L  ong-Term Ventilator-Dependent Patients: Noninvasive Ventilation ���������������������������������������������������������������������������� 191 Murat Erdoğan, İrem Okuducu Teran, and Dilek Özcengiz Part VI Noninvasive Ventilation: Chronic Respiratory Failure 20 Sleep-Related Breathing Disorders���������������������������������������������������������� 199 Alberto Castagna, Paola Elisa Scarpino, Ciro Manzo, and Giovanni Ruotolo 21 Psychotic  Disorders and NIV�������������������������������������������������������������������� 205 Francesca Neviani and Andrea Fabbo 22 Neurodegenerative Disorders/Dementia�������������������������������������������������� 215 Barbara Manni, Lucia Bergamini, and Marina Turci 23 Chronic Neurological Disorders �������������������������������������������������������������� 227 Angela Mancini and Andrea Fabbo Part VII Outcome, Quality of Life, Palliative Care 24 Risk  Factors for Prolonged Psychiatric Morbidity During Noninvasive Ventilator Support�������������������������������������������������� 249 Soner Çakmak 25 Neurology  and Psychiatric Sequelae of Intensive Care: Impact on Quality of Life���������������������������������������������� 263 Rafael Soler, Orestes Herrera, and Antonio M. Esquinas 26 Neurology  and Psychiatric Disorders: Long-Term Implications for the Healthcare System�������������������������������������������������� 275 Angela Mancini, Antonella Pellitta, and Andrea Fabbo 27 Neurocognitive  and Emotional Morbidity and Quality of Life�������������������������������������������������������������������������������������������� 291 Valentina Reda 28 Psychological,  Social, and Economic Impacts ���������������������������������������� 299 Annalisa Baglieri and Valentina Reda 29 Neurology  and Psychiatric Cognitive Recovery�������������������������������������� 313 Chiara Galli 30 Non Invasive Ventilation���������������������������������������������������������������������������� 319 Nicola Vargas, Loredana Tibullo, Angela Pagano, and Andrea Fabbo 31 Neuropsychiatric  Disorders in Pulmonary Rehabilitation�������������������� 329 Sulochana Kumari, Kishore Kumar, and Meenakshi Narasimhan

viii

Contents

Part VIII Treatment: Interventions and Prevention 32 P  hysical Activity/Emotional Response in Non-invasive Ventilator Users ������������������������������������������������������������������ 339 Giuseppe Attisani, Alessandra Pascale, Nazario Maria Manzo, and Alberto Castagna 33 New  Technologies (Tele-Health and Other Trends) Directed in Neurology and Psychiatric Disorders in Home Care���������������������������������������������������������������������������� 345 Angela Mancini and Andrea Fabbo 34 Prevention  Tools for Neurology and Psychiatric Disorders in Noninvasive Ventilation (Delirium Prevention/Management Sleep Promotion)�������������������������������������������� 367 Federica Boschi, Barbara Manni, and Andrea Fabbo Part IX Further Research 35 The  Role of Neurocognitive Disorders in Sustaining “Ageism as a Key Factor for Noninvasive Ventilation Failure”������������ 385 Vincenza Frisardi and Maria Luisa Davoli 36 Neuropsychiatric Disorders During Non-­Invasive Ventilation�������������� 403 Alberto Castagna, Giuseppina Fabbo, and Carmen Ruberto

Abbreviations

[ΔP(A-a)] Alveolar-arterial gradient ABB Acid-base balance AD Alzheimer disease AECOPD Acute exacerbation of chronic obstructive pulmonary disease AG Anion gap AHCD Advanced Health Care Directives ALS Amyotrophic lateral sclerosis AOC Acute-on-chronic respiratory failure APA American Psychiatric Association APACHE Acute Physiology AND Chronic Health Evaluation ARDS Acute respiratory distress syndrome ARF Acute respiratory failure BBB Blood-brain barrier BDI Beck Depression Inventory BMI Body Mass Index CAP Community acquired pneumonia CBT Cognitive-behavioral therapy-based approach CCHS Congenital central hypoventilation syndrome CCQ Clinical C.O.P.D. Questionnaire CO2 Carbon dioxide COPD Chronic obstructive pulmonary disease CPAP Continuous positive airway pressure CPAP Continuous positive air pressure CPE Cardiogenic pulmonary edema CRF Chronic respiratory failure CT Computed tomography CURB-65 Criteria score DMC Decision-making capacity DMD Duchenne muscular dystrophy DNI Do not intubate order DSM Diagnostic and statistical manual of mental disorders DTI Diffusion tensor imaging EEG Electro-encephalogram FEV1 Forced expiratory volume in one second ix

x

FVC Forced vital capacity GABA Gamma-aminobutyric acid GCSs Glasgow Coma Scale score GRK2 G-protein-coupled receptor kinase 2 HADS Hospital Anxiety and Depression scale score HCPs Healthcare professionals HDRCU High Dependence Respiratory Care Unit HSCL-25 Hopkins Symptom Checklist ICP Individual care plan ICU Intensive care unit LC Locus coeruleus LRTI Lower respiratory tract infections LTE Limitation of therapeutic effort MAO Monoamine oxidase MAOIs Monoamine oxidase inhibitors MCI Mild cognitive impairment MDD Major depressive disorder MND Motor neuron disease MND Motoneuron disease MV Mechanical ventilation NET Norepinephrine transporter NIMV Noninvasive mechanical ventilation NIPPV Noninvasive positive pressure ventilation NIV Noninvasive mechanical ventilation NIV Noninvasive ventilation NMDs Neuromuscular diseases OSA Obstructive sleep apnea OSAS Obstructive sleep apnea syndrome paCO2 Partial pressure of carbon dioxide PACO2 Alveolar carbon dioxide pressure PaCO2 Arterial carbon dioxide pressure PACO2 Carbon dioxide alveolar pressure PaCO2 Carbon dioxide arterial pressure paO2 Partial pressure of oxygen PaO2 Oxygen arterial pressure PAO2 Alveolar oxygen pressure PAO2 Arterial oxygen pressure PAO2 Oxygen alveolar pressure PEEP Positive end-expiratory pressure PSI Pneumonia Severity Index PSV Pressure support ventilation pts Patients PTSD Posttraumatic stress disorders RF Respiratory failure RHDCU Respiratory High Dependency Care Unit

Abbreviations

Abbreviations

RMU SAE SCAP Serotonin SERT SMA SSRIs TCAs V/Q mismatch VBM

xi

Respiratory monitoring unit Sepsis-associated encephalopathy Severity Commune-Acquired Pneumonia score 5-HT2C receptors Serotonin transporter Spinal muscular atrophy Selective serotonin reuptake inhibitors Tricyclic antidepressants Ventilation-perfusion imbalance Voxel-based morphometry

Part I Neuropsychiatric and Lung Physiology

1

Case Report: Delirium Permanence During Resolution Phase of Massive Pneumonia in Patient with COPD Exacerbation Corrado Mollica, Enrico Maialetti, Francesco Alessandri, and Daniela Sollazzo

1.1 Clinical Case At the time of admission into the hospital, a 52-year-old patient presented drowsiness, a confusional state with spatial-temporal disorientation, ideomotor apraxia, and confabulation. The patient reported an accidental fall that occurred 36 h earlier, during an episode of atrial flutter at frequency 300/m′ and conduction 2:1, with loss of consciousness followed by drowsiness, retrograde amnesia, and temporospatial disorientation. The patient was treated, for about 10 years, with oral hypoglycaemic drugs for type 2-diabetes mellitus, resulting once in keto-acidemic coma. Objective examination on admission: cyanosis, hyperpyrexia (38.7  °C), HR: 104/m′, RR: 24/m′, AP: 150/90, isochoria, isocyclia, and pupillary normoreflexia; superficial and deep reflexes intact and Babinski negative. ESR I^h: 60, Leukocytosis (11,500 × 103/μL) neutrophilic (84.8%), Glycemia: 248 mg/dL, Urea (BUN level: 6.5 mmol/L (nv: 3.6–7.1); Ketonuria ++, ALT: 94 U/L, AST: 77 U/L, LDH: 654 mU/ mL (nv: 80–300), CPK: 147 U/L (nv: 60–190). Acid–base balance (ABB) (arterial sample) (FiO2: 21%): PaO2: 38 mmHg, PaCO2: 66 mmHg, pH: 7.32, SaO2: 68%, O2ct: l7.5, HCO3−: 33 mEq/L, PaO2/FiO2 = 180, ΔP(A − a)O2: 29.23 mmHg (range: C. Mollica (*) Respiratory High Dependency Care Unit (STIRS), “Forlanini-S.Camillo” Hospital, Rome, Italy E. Maialetti Casa della Salute, Ostia, Rome, Italy F. Alessandri Department of Anaesthesiology, “Sapienza” University of Rome, Policlinico Umberto I, Rome, Italy e-mail: [email protected] D. Sollazzo Neuro-Pathophysiology Unit, “Forlanini-S.Camillo” Hospital, Rome, Italy © The Author(s), under exclusive license to Springer Nature Switzerland AG 2023 A. M. Esquinas et al. (eds.), Noninvasive Mechanical Ventilation and Neuropsychiatric Disorders, https://doi.org/10.1007/978-3-031-27968-3_1

3

4

C. Mollica et al.

5–20), Glasgow Coma Scale: 10 (Eye-opening: 3; Verbal response: 3; Motor response: 4); APACHE II score = 23 (Table 1.1). X-ray: right chest showed “morphologically irregular opacity in right subclavear region with subtotal opacification of the entire omolateral hemithorax” (Fig. 1.1). Fibrobronchoscopy: perviousness of the gill system with a small mucopurulent secretion. After laboratory analysis, Table 1.1  APACHE II, Pneumonia severity and risk delirium scores in a COPD patient with ARF Patient data APACHE II CRB-65 SCAP PSI/PORT T° 38.7 1 RR 24/m 0 HR 104/m 0 0 MPA 110 mmHg 2 0 WC 11,500 × 103/ 0 μL Glycemia 248 mg/dL BUN 6.5 mmol/L 0 AST 77 U/L ALT 94 U/L LDH 654 mU/mL CPK 147 U/L PaO2 38 mmHg 4 6 10 PaCO2 66 mmHg pH 7.32 2 30 SaO2 68% O2ct 17.5 HCO3− 33mEq/L 1 Ht 46% 1 FiO2 21% PaO2/FiO2 180 PaO2/PAO2 0.56 PAO2 67,23 mmHg ΔP(A−a)O2: 29.23 mmHg Age 52 2 0 G.C. score 10 5 C.O.P.D. 5 X-ray 5 Confusion 1 5 20 Na 142 K 3.5 Cl 92 Creatin 1.04 mg/ 0 dL TOTAL 23 1 16 60 Patient data Age 52

PRE-DELIRIC score 18

1  Case Report: Delirium Permanence During Resolution Phase of Massive…

5

Table 1.1 (continued) G.C. score 10 APACHE II score Administ. morphine Sedatives Urgent admission BUN 6.5 mmol/L Infection Admission category Met. acidosis (A.G. = 17) Total

No coma 1 0 0 YES 1 YES Medical YES 20%

APACHE II score: Acute Physiology AND Chroni Health Evaluation, CRB-65 score: confusion, uremia, respiratory frequency, low blood pressure, age 65 years, SCAP score: Severity CommuneAcquired Pneumonia, PSI/PORT score: Pneumonia Severity Index, PRE-DELIRIC score (Second edition): age, APACHE II score, admission group, emergency admission, infection, coma, sedation, morphine use, urea level, and metabolic acidosis

this showed cytology free from neoplastic agents and gave rise to a conspicuous development of Candida. Serological positivity for influenza A virus and T8-lymphocytes increases (Helper/Suppressor > H/S). A combination therapy with amoxicillin/clavulanate and macrolide over 6 days was administered. Continuous Positive Air Pressure (CPAP) via face mask (initial CPAP setting at 2 cmH2O, then adjusted up to 8 cmH2O) was administered by Puritan Bennett 7200 (Puritan Bennett Co., Overland Park, KS), in the early hours of admittance in Respiratory High Dependency Care Unit (RHDCU), using FiO2 at variable flow (FiO2 range: 40–35%), necessary to maintain SaO2 ≥ 90%, pending resolution of the pneumonia, thanks to promptly initiated antibiotic therapy. Few hours later a bi-level ventilation was administered (Pressure Support increased from 5 a 10 cmH2O) with Positive End Expiratory Pressure (PEEP da 2 a 5 cmH2O) in order to obtain an exhaled tidal volume greater than 6 mL/kg, disappearance of accessory muscle activity, and greater patient comfort. The permanence of an “oneiroid” state in the patient prompted to perform an electroencephalogram (EEG): “prevalence of theta activity at 4–6 Hz, over the whole range, interspersed with recurrent sequences of alpha activity at 7–8 Hz, (in a widely slowed down trace)…” (Fig. 1.2). The condition was not accompanied by alterations in the acid–base balance or glycemia. Computed tomography (CT) Scan of the Brain (CT-brain scans) was negative for tono-densitometric alterations. In the following days, we witnessed a gradual psycho-sensory improvement going in parallel with the clinical-Rx thoracic graph (Figs. 1.3 and 1.4); then he was transferred to the medical ward for further treatment. The patient was eventually discharged after few days in early supported discharge because of the improvement of the overall clinical picture.

6

C. Mollica et al.

Fig. 1.1  At admittance X-ray (length = 3031 Pixels; height = 1992 Pixels; 2400 dpi resolution)

Fig. 1.2  EEG: electroencephalogram: “prevalence of theta activity at 4–6  Hz, over the whole range, interspersed with recurrent sequences of alpha activity at 7–8 Hz”

1  Case Report: Delirium Permanence During Resolution Phase of Massive… Fig. 1.3  During treatment X-ray (length = 3031 Pixels; height = 1992 Pixels; 2400 dpi resolution)

Fig. 1.4  At discharged X-ray (length = 3031 Pixels; height = 1992 Pixels; 2400 dpi resolution)

7

8

C. Mollica et al.

1.2 Discussion 1.2.1 Definition of Delirium Delirium is an acute and fluctuating alteration of the normal mental state with reduced awareness and disturbance of attention [1]. It is usually a reversible neuropsychiatric syndrome that frequently occurs in critically ill patients. In the English literature, synonyms of delirium such as the Intensive Care Unit syndrome, acute brain dysfunction, acute brain failure, psychosis, confusion, and encephalopathy are widely used. This often leads to scientific “confusion” regarding published data and methodology within studies, which is further exacerbated by organizational, cultural and language barriers [2].

In Morandi et al. (2008) only 54% of 24 authors use the term “delirium” to indicate the disorder as defined by the DSM-IV, “… as an acute change in mental status, inattention, disorganized thinking and altered level of consciousness…” [2]. Our patient was considered to suffer from delirium based on their meeting the DSM IV criteria for delirium [3]; the presence of transient delirium was acknowledged via psychiatric evaluation and defined as “oneiroid state”. As well as convulsive causes, nonconvulsive seizure is also a recognized cause of altered consciousness in critically ill patients. In patients admitted to intensive care unit (ICU) “delirium” usually features more than one cause, the most common risk factors are: hypoxemia, infection, acute metabolic acidosis, alkalosis, electrolyte imbalance, drugs/dehydration, level of pain, and psychiatric illness [4]. As to our patient, the presence of type 2-diabetes mellitus, infection, and obstructive lung disease with respiratory failure (PaCO2 greater than 45 mmHg, PaO2 less than 55 mmHg, and oxygen saturation less than 88%) seemed to be the only risk factors conducive to delirium [5]. Indeed, neither previous history of psychiatric illness nor previous ICU stay was present. It is worthwhile to highlight such an aspect for in chronically critically ill patients (pts) a neurological disorder as the cause of respiratory failure was found 2.4 times more frequent in the persistent delirium group than in the transient-­ delirium group (26% versus 10%, p = 0.003) [6]. It is equally well known the capacity of delirium to modify the outcome of an illness much like its severity degree. In short, the more severe the illness is, the likelier the possibility of the onset of delirium, leading in turn to poorer clinical outcomes [7]. As it happens, delirium is associated with the presence of a more severe illness score (Acute Physiology AND Chronic Health Evaluation (APACHE II) [8] not least in pts. during Weaning from Prolonged Mechanical Ventilation [9] and is equally correlated to poor prognosis, with a mortality rate of up to 63% in ICU pts. admitted for septic encephalopathy with a Glasgow Coma Scale score (GCSs) [10] between 3 and 8 [11].

1  Case Report: Delirium Permanence During Resolution Phase of Massive…

9

1.2.2 Risk Factors for Delirium To calculate the risk of delirium in our patient we used the PRE-DELIRIC score (second edition) which includes 10 predictors [age, APACHE II score, admission group (medical, surgical, trauma, and neurologic), emergency admission, infection, coma, sedation, morphine use, urea level, and metabolic acidosis], and which relies on logistic regression (Table 1.1) [12]. Delirium was also assessed by using EVIDENCIO Medical Prediction Model [Evidencio v3.16 © 2015–2023], and it turned out to be equal to 20% [13]. According to van den Boogaard et al. (2012) [14], revised by using the Mayo Delirium Prediction (MDP) tool [15] on a toll of 120.764 people classified into the three groups—low (25/30). Indeed only seven subjects with moderate cognitive impairment (MMSE26/30. Mild cognitive impairment rates between 26/30 and 21/30. Moderate cognitive impairment rates MMSE between 20/30 and 10/30. Sever cognitive impairment is with MMSE 6.5 kPa • (European ALS/MND Consortium) According to more recent NICE guidelines published in 2016 and updated in 2019, patients with an FVC or VC less than 50% predicted or less than 80% predicted and with signs and symptoms suggesting respiratory function impairment or a sniff nasal inspiratory pressure less than 40  cmH2O should be started NIV, as showed in Fig. 23.1 [42, 45]. Despite these evidence, there are also several hypotheses that suggest more early initiation of NIV (Lechtzin N, Scott Y). The NICE guidelines underlined also that the decision of starting NIV must be proposed by a multidisciplinary team. The patient must be informed about the benefits and about the difficulties that he can experiment during the treatment [46]. NIV can be considered also as a treatment for patients in terminal phase of the disease and it seems to be not associated with any adverse effects [47]. Bi-level positive pressure device is more used in patients with ALS [48], while continuous positive pressure ventilation (CPAP) is not usually appropriate for these patients. The treatment with nIV in MND may be hampered by reasons that reduce its compliance. For example, they can develop sialorrhea primarily due to bulbar dysfunction with poor coordination of the tongue and palate. This could result in poor performance with NIV and lead to intolerance of a life-prolonging treatment [16]. Also obstruction related to abnormal function of the vocal cords and increase in risk of aspiration are frequent [48]. Hence to improve the compliance in these patients, it can be useful to give attention to secretion management and humidification. Another element to be considered in the compliance of these patients is that the setting of the parameters used in NIV must be adjusted and modified during the disease

232

A. Mancini and A. Fabbo

Fig. 23.1  NICE guideline on the introduction of NIV in those with MND

progression. Therefore, these patients present often cognitive impairment like frontotemporal dementia, psychiatric conditions which can range from apathy, behavioural and mood changes, and condition of social isolation. All of these disorders can lead to discontinuation of therapy [38, 49].

23.3 Duchenne Muscular Dystrophy (DMD) Duchenne muscular dystrophy (DMD) is the most common muscular dystrophy of childhood [50]. It is a genetic disease, inherited as an X-linked recessive disorder (Xp2.1), that lead to the complete absence of the protein dystrophin in cytoskeletal [51] with consequent progressive atrophy, weakness and dysfunction in skeletal, smooth, and cardiac muscle [52, 53]. The symptoms may include fatigue, frequent falls, progressive difficulty in walking, learning difficulties, and mental retardation. Respiratory failure is due to paralysis of respiratory muscles that causes a decrease in forced vital capacity (FVC) from 12 years old. FVC decreases by 5–10% per year during the disease [54]. At the age of about 20 daytime respiratory failure with hypercapnia develops [55]. Cardiac and respiratory failure are the most common cause of death, at the age of about 20–30 with conventional therapy [52, 56, 57]. The correct management of respiratory failure in these patients has been widely discussed in literature, more specific there are discordant hypothesis about the use of invasive versus non-­invasive ventilation. Both invasive and non-invasive ventilation present some risks, like, in

23  Chronic Neurological Disorders

233

case of invasive ventilation: accidental disconnection, ventilator failure, infection, fistula, mucus plugging, or haemorrhage for tracheostomy ventilation. The risks of NIV can be losing access to the non-invasive interface, ventilator failure, or airway congestion [58]. Nevertheless, non-invasive management is associated with fewer respiratory hospitalizations, lower costs [59], and more compliance than invasive ventilation, thanks to its safety, convenience, comfort, and general more acceptability [60]. There are several studies that have not found correlation between NIV and improve in survival [50, 61] and about the evidence of more benefit with invasive ventilation, even more when conducted with mini-tracheotomy to stabilize the vital capacity in DMD patients [62, 63]. According to other studies, the survival seems to be the same in patients in continuous NIV and in tracheostomy ventilation [64] even more when NIV is used also for assisted cough [65]. A predominately nocturnal NIV use prolongs survival in these patients with a survival that can reach to 25.3–30.4  years [66–68]. Hence NIV is currently considered the first-line treatment in DMD. During the first years of respiratory dysfunction, nocturnal NIV is used to treat symptoms that develop during the sleep [69] and then it can be extended also to diurnal NIV with cough assistance [33, 70, 71]. About the indications to start NIV, currently, it is indicated when vital capacity drops below 20% of the theoretical value, or PaCO2 level is above or equal to 45 mmHg [50, 72]. However, according to some studies, the preventive use of NIV in patients with asymptomatic Duchenne muscular dystrophy before the development of nocturnal or diurnal ventilator insufficiency is not associated with better survival [30]. During the progression of the disease, the severe bulbar dysfunction or the ineffectiveness in cough assistance leads to frequent tracheal aspiration through tracheotomy. This is one of the moments to switch to invasive ventilation [72–74]. The switch occurs also when NIV becomes ineffective or poorly tolerated [72–74] or in case of an episode of acute respiratory failure. In this case it may be possible to return to non-invasive ventilation [71, 75].

23.4 Spinal Muscular Atrophy (SMA) Spinal muscular atrophy (SMA) is a genetic disease, due to the mutations in the survival of motor neuron (SMN1 or SMN2) gene. It includes a wide range of phenotypes: very weak infants unable to sit without support (type 1), non-ambulant children able to sit independently (type 2), up to ambulant children (type 3), and adults (type 4) [76, 77]. The type 1 includes type 1B in which symptoms onset